View Valuation4DMedical 향후 성장Future 기준 점검 2/64DMedical (는) 각각 연간 84.3% 및 85.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 86.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -4.5% 로 예상됩니다.핵심 정보84.3%이익 성장률86.50%EPS 성장률Healthcare Services 이익 성장22.3%매출 성장률85.3%향후 자기자본이익률-4.54%애널리스트 커버리지Low마지막 업데이트03 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 014DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,067,797 Price\Range: AUD 5.9 Discount Per Security: AUD 0.236 Transaction Features: Subsequent Direct Listing공시 • Mar 304Dmedical Limited Announces Commercial Launch of CT:VQ Imaging Technology in European Union4DMedical Limited announced that its latest imaging technology, CT:VQ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets. CT:VQ is the world's first and only non-contrast, ventilation-perfusion imaging technology, providing quantitative functional lung insights from routine non-contrast CT scans without the need for radiotracers or specialised nuclear medicine infrastructure. Pulmonary disease is fundamentally functional—defined by abnormalities in ventilation and perfusion—yet most routine imaging available to radiologists and pulmonologists remains purely structural. CT:VQ bridges that gap by generating ventilation and perfusion maps allowing clinicians to visualize regional lung function with the anatomical clarity of CT. For large medical institutions, CT:VQ is designed to fit within existing CT-based workflows and infrastructure. CT:VQ offers relief from long-standing constraints associated with conventional nuclear VQ imaging, including radiotracer availability, workforce limitations and operational complexity. The European market represents a significant opportunity for advanced cardiothoracic imaging. With a population of more than 450 million, a highly developed hospital-based imaging infrastructure and an extensive installed base of CT scanners, the EU is well positioned for adoption of CT-based functional lung imaging. 4DMedical estimates that approximately 400,000 nuclear VQ scans are performed annually across the EU, underscoring the scale of clinical need. The CE Mark follows growing U.S. momentum for CT:VQ, which is now deployed at six leading academic medical centres: Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, University of Chicago Medicine, and the recently announced initial deployment at Mayo Clinic. 4DMedical believes this early adoption by major U.S. institutions demonstrates strong interest in CT:VQ among leading radiology and pulmonary teams and provides a blueprint for expansion into Europe. 4DMedical said it is now advancing plans to expand commercial engagement across Europe and to work with leading hospitals and clinicians on adoption, evaluation and research initiatives for CT:VQ. CT:VQ is 4DMedical's proprietary ventilation-perfusion imaging solution that generates functional lung information from non-contrast CT scans. Built on the Company's patented XV Technology, CT:VQ is designed to provide quantitative ventilation and perfusion insights within familiar CT workflows, without requiring radiotracers.공시 • Mar 274DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million.4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,067,797 Price\Range: AUD 5.9 Discount Per Security: AUD 0.236 Transaction Features: Subsequent Direct Listing공시 • Jan 154DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,806,185 Price\Range: AUD 3.8 Discount Per Security: AUD 0.19공시 • Jan 02+ 1 more update4DMedical Limited Appoints Julian Sutton as Executive Director4DMedical Limited on January 2, 2026 announced the appointment of Julian Sutton Julian Sutton as Executive Director, effective January 2, 2026. Julian is an early investor in 4DMedical and has served as a Non-Executive Director since September 2017, developing deep expertise in the Company's technology, strategy, and commercial operations. Over this period, he has worked closely with the executive team on capital strategy, corporate governance, and investor relations, playing an instrumental role in securing funding to advance the Company's product development, regulatory and commercial objectives. Julian’s appointment to the executive team follows a period of significant commercial momentum for 4DMedical. With CT:VQ™ now FDA-cleared and actively deployed at leading U.S. academic medical centres, and a transformative global distribution agreement with Philips recently announced, the Company is well positioned for accelerated scale-up. This appointment formalises Julian’s strategic role at a pivotal inflection point in the Company's commercialisation. Julian Sutton’s term is set for three years with a three-month notice period.공시 • Sep 04+ 1 more update4DMedical Limited, Annual General Meeting, Oct 30, 20254DMedical Limited, Annual General Meeting, Oct 30, 2025.공시 • Feb 21+ 1 more update4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 12,941,176 Price\Range: AUD 0.425 Discount Per Security: AUD 0.0255 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Dec 204DMedical Limited Announces John Livingston Reverts to Non-Executive Director Position, Effective 1 January 20254DMedical Limited announced that Director John Livingston is to revert to a Non-Executive Director position with the Company, effective 1 January 2025. John's terms of appointment as a non-executive director will be on the same basis as other non-executive directors.공시 • Sep 244DMedical Limited, Annual General Meeting, Nov 20, 20244DMedical Limited, Annual General Meeting, Nov 20, 2024.공시 • Dec 164DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,303,797 Price\Range: AUD 0.79 Discount Per Security: AUD 0.0395 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Dec 114DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,303,797 Price\Range: AUD 0.79 Discount Per Security: AUD 0.0395 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Nov 234DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software4DMedical has received FDA clearance for its CT-based ventilation product (CT LVAS(TM). CT LVAS, designed for use with computed Tomography scans, joins 4D Medical's XV LVAS(R) imaging software cleared for use with fluoroscopy In the United States. The FDA clearance for CT LVAS dovetails with the upcoming 4DMedical product, CT:VQ(TM). CT:VQ will enable quantitative perfusion (blood flow) data and visualizations to be extracted from CT scans. Standard CT images provide clinicians with structural detail about patients' lungs--from which they try to inferred information about disease and function. CT LVAS adds a wealth of data on lung performance on top of the structural detail of CT scans. This capability fills an information gap that enables radiologists to provide the objective, data-driven information that could materially inform diagnosis and treatment options. CT LVAS software processes existing CT scans using sophisticated algorithms derived from aerospace technology. These highly detailed reports include color-coded images of regional airflow and lung ventilation--overlayed on the patient's CT scan. CT LVAS uses a software-as-a-service model and requires no new capital equipment. Scans from existing CT equipment are uploaded for processing, where they are analyzed and returned to the radiologist as the Ventilation Report. CT LVAS measures lung ventilation in tens of thousands of locations in the lungs. The Regional Ventilation Visualizations provide region-specific ventilation at deep inspiratory breath-hold for a mid-coronal slice and threeaxial slices--Upper, Middle, and Lower. The regional ventilation data is quantified in lung volume change and regional lung ventilation heterogeneity.공시 • Nov 014DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee4DMedical Limited announced that Evonne Collier has resigned as a non-executive director, Chair of the Remuneration and Nomination Committee.공시 • Sep 254DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors4DMedical Limited announced the appointment of Dr. Geraldine McGinty, MD, to the Company’s Board of Directors. Professor of Clinical Radiology and Population Health Sciences, and a certified radiologist practising at Weill Cornell Medical Center, Dr. McGinty is an accomplished academic, researcher, administrator and health care economist. In 2018, Dr. McGinty became the first woman elected as Chair of the American College of Radiology’s (ACR) board of Chancellors, making a significant contribution to the ACR through a reorganisation of its Data Science Institute, enabling greater board communication and diversity of opinion. The ACR is "The Voice of Radiology" in matters of legislation and regulation, and is responsible for guiding radiology reimbursement and coding issues, including relative value units, managed care, alternative payment models, and Medicare regulations. Prior to this, Dr. McGinty headed up the ACR’s Commission on Economics. The Commission’s work often is used as background material and evidence for ACR congressional and state legislative efforts as well as communications with the CMS (Centers for Medicare & Medicaid Services), policy makers, and other medical insurers. Her corporate governance experience includes serving on the Board of NextGen Healthcare, and as a Non-Executive Director with the Industrial Development Authority (IDA) of the Republic of Ireland, chairing its Audit, Risk and Finance Committee. Dr. McGinty is also a member of the Governing Authority of the University of Galway in Ireland. In her various leadership roles, Dr. McGinty has been a powerful and influential voice for women in medical imaging. She has also been instrumental in identifying and mentoring radiologists who push to address health disparities in research, advocacy efforts, artificial intelligence development, and medical student recruitment. Dr. McGinty is highly qualified in clinical practice and management, possessing both a medical degree from the National University of Ireland and a master’s degree in business administration from Columbia University. Dr. McGinty’s academic stature is reflected in her appointment as Professor of Clinical Radiology at Weill Cornell Medicine where she is concurrently Senior Associate Dean of Clinical Affairs. In 2017, Dr. McGinty was appointed as founding Academic Director for the Executive MBA and Masters in Healthcare Leadership program delivered jointly by Weill Cornell and the Cornell University SC Johnson School of Business, a role she performed until 2019. Dr. McGinty’s published work has focused on payment models for imaging, most recently a bundled payment for breast cancer screening. Recently she has focused on the impact of Artificial Intelligence on Medical Imaging and has spoken at the Turing Institute and to the WHO Focus Group on AI in Healthcare on this topic. As a member of the American Medical Association’s Relative Value Unit Update Committee from 2012- 2016, Dr. McGinty was instrumental in recommending reimbursement policy to Medicare, thereby impacting the economics of the entire U.S. healthcare delivery system. In addition, from 2015 to 2021, Dr. McGinty was Chief Strategy and Contracting Officer within Weill Cornell responsible for fee-for-service and value-based payment arrangements.공시 • Aug 294DMedical Limited, Annual General Meeting, Nov 02, 20234DMedical Limited, Annual General Meeting, Nov 02, 2023, at 10:00 AUS Eastern Standard Time.이익 및 매출 성장 예측OTCPK:FDMD.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202855-8-28-336/30/202724-26-24-2136/30/20267-107-33-30212/31/20256-173-34-33N/A9/30/20256-101-35-34N/A6/30/20256-30-36-34N/A3/31/20256-27-34-32N/A12/31/20246-32-32-30N/A9/30/20245-34-32-31N/A6/30/20244-36-32-31N/A3/31/20242-33-33-32N/A12/31/20231-31-34-32N/A9/30/20231-31-29-28N/A6/30/20231-31-24-23N/A3/31/20231-30-19-18N/A12/31/20221-28-15-13N/A9/30/20221-26-22-19N/A6/30/20221-25-29-25N/A3/31/20221-23-28-24N/A12/31/20210-21-26-23N/A9/30/20210-21-21-19N/A6/30/20210-21-15-15N/A3/31/20210-26-16-15N/A12/31/20200-30-16-15N/A9/30/20201-26-12-11N/A6/30/20201-22-9-8N/A3/31/20202-16-8-7N/A12/31/20192-9-7-6N/A9/30/20191-8N/A-6N/A6/30/20191-6N/A-6N/A6/30/20181-4N/A-3N/A6/30/20171-4N/A-2N/A12/31/20150-1N/A-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: FDMD.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: FDMD.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: FDMD.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: FDMD.F 의 수익(연간 85.3%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: FDMD.F 의 수익(연간 85.3%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: FDMD.F는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 02:18종가2026/05/21 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스4DMedical Limited는 6명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관John HesterBell PotterJohn CampbellJefferies LLCStephen BlaggJefferies LLC3명의 분석가 더 보기
공시 • Apr 014DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,067,797 Price\Range: AUD 5.9 Discount Per Security: AUD 0.236 Transaction Features: Subsequent Direct Listing
공시 • Mar 304Dmedical Limited Announces Commercial Launch of CT:VQ Imaging Technology in European Union4DMedical Limited announced that its latest imaging technology, CT:VQ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets. CT:VQ is the world's first and only non-contrast, ventilation-perfusion imaging technology, providing quantitative functional lung insights from routine non-contrast CT scans without the need for radiotracers or specialised nuclear medicine infrastructure. Pulmonary disease is fundamentally functional—defined by abnormalities in ventilation and perfusion—yet most routine imaging available to radiologists and pulmonologists remains purely structural. CT:VQ bridges that gap by generating ventilation and perfusion maps allowing clinicians to visualize regional lung function with the anatomical clarity of CT. For large medical institutions, CT:VQ is designed to fit within existing CT-based workflows and infrastructure. CT:VQ offers relief from long-standing constraints associated with conventional nuclear VQ imaging, including radiotracer availability, workforce limitations and operational complexity. The European market represents a significant opportunity for advanced cardiothoracic imaging. With a population of more than 450 million, a highly developed hospital-based imaging infrastructure and an extensive installed base of CT scanners, the EU is well positioned for adoption of CT-based functional lung imaging. 4DMedical estimates that approximately 400,000 nuclear VQ scans are performed annually across the EU, underscoring the scale of clinical need. The CE Mark follows growing U.S. momentum for CT:VQ, which is now deployed at six leading academic medical centres: Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, University of Chicago Medicine, and the recently announced initial deployment at Mayo Clinic. 4DMedical believes this early adoption by major U.S. institutions demonstrates strong interest in CT:VQ among leading radiology and pulmonary teams and provides a blueprint for expansion into Europe. 4DMedical said it is now advancing plans to expand commercial engagement across Europe and to work with leading hospitals and clinicians on adoption, evaluation and research initiatives for CT:VQ. CT:VQ is 4DMedical's proprietary ventilation-perfusion imaging solution that generates functional lung information from non-contrast CT scans. Built on the Company's patented XV Technology, CT:VQ is designed to provide quantitative ventilation and perfusion insights within familiar CT workflows, without requiring radiotracers.
공시 • Mar 274DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million.4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,067,797 Price\Range: AUD 5.9 Discount Per Security: AUD 0.236 Transaction Features: Subsequent Direct Listing
공시 • Jan 154DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,806,185 Price\Range: AUD 3.8 Discount Per Security: AUD 0.19
공시 • Jan 02+ 1 more update4DMedical Limited Appoints Julian Sutton as Executive Director4DMedical Limited on January 2, 2026 announced the appointment of Julian Sutton Julian Sutton as Executive Director, effective January 2, 2026. Julian is an early investor in 4DMedical and has served as a Non-Executive Director since September 2017, developing deep expertise in the Company's technology, strategy, and commercial operations. Over this period, he has worked closely with the executive team on capital strategy, corporate governance, and investor relations, playing an instrumental role in securing funding to advance the Company's product development, regulatory and commercial objectives. Julian’s appointment to the executive team follows a period of significant commercial momentum for 4DMedical. With CT:VQ™ now FDA-cleared and actively deployed at leading U.S. academic medical centres, and a transformative global distribution agreement with Philips recently announced, the Company is well positioned for accelerated scale-up. This appointment formalises Julian’s strategic role at a pivotal inflection point in the Company's commercialisation. Julian Sutton’s term is set for three years with a three-month notice period.
공시 • Sep 04+ 1 more update4DMedical Limited, Annual General Meeting, Oct 30, 20254DMedical Limited, Annual General Meeting, Oct 30, 2025.
공시 • Feb 21+ 1 more update4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 12,941,176 Price\Range: AUD 0.425 Discount Per Security: AUD 0.0255 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Dec 204DMedical Limited Announces John Livingston Reverts to Non-Executive Director Position, Effective 1 January 20254DMedical Limited announced that Director John Livingston is to revert to a Non-Executive Director position with the Company, effective 1 January 2025. John's terms of appointment as a non-executive director will be on the same basis as other non-executive directors.
공시 • Sep 244DMedical Limited, Annual General Meeting, Nov 20, 20244DMedical Limited, Annual General Meeting, Nov 20, 2024.
공시 • Dec 164DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,303,797 Price\Range: AUD 0.79 Discount Per Security: AUD 0.0395 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Dec 114DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,303,797 Price\Range: AUD 0.79 Discount Per Security: AUD 0.0395 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Nov 234DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software4DMedical has received FDA clearance for its CT-based ventilation product (CT LVAS(TM). CT LVAS, designed for use with computed Tomography scans, joins 4D Medical's XV LVAS(R) imaging software cleared for use with fluoroscopy In the United States. The FDA clearance for CT LVAS dovetails with the upcoming 4DMedical product, CT:VQ(TM). CT:VQ will enable quantitative perfusion (blood flow) data and visualizations to be extracted from CT scans. Standard CT images provide clinicians with structural detail about patients' lungs--from which they try to inferred information about disease and function. CT LVAS adds a wealth of data on lung performance on top of the structural detail of CT scans. This capability fills an information gap that enables radiologists to provide the objective, data-driven information that could materially inform diagnosis and treatment options. CT LVAS software processes existing CT scans using sophisticated algorithms derived from aerospace technology. These highly detailed reports include color-coded images of regional airflow and lung ventilation--overlayed on the patient's CT scan. CT LVAS uses a software-as-a-service model and requires no new capital equipment. Scans from existing CT equipment are uploaded for processing, where they are analyzed and returned to the radiologist as the Ventilation Report. CT LVAS measures lung ventilation in tens of thousands of locations in the lungs. The Regional Ventilation Visualizations provide region-specific ventilation at deep inspiratory breath-hold for a mid-coronal slice and threeaxial slices--Upper, Middle, and Lower. The regional ventilation data is quantified in lung volume change and regional lung ventilation heterogeneity.
공시 • Nov 014DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee4DMedical Limited announced that Evonne Collier has resigned as a non-executive director, Chair of the Remuneration and Nomination Committee.
공시 • Sep 254DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors4DMedical Limited announced the appointment of Dr. Geraldine McGinty, MD, to the Company’s Board of Directors. Professor of Clinical Radiology and Population Health Sciences, and a certified radiologist practising at Weill Cornell Medical Center, Dr. McGinty is an accomplished academic, researcher, administrator and health care economist. In 2018, Dr. McGinty became the first woman elected as Chair of the American College of Radiology’s (ACR) board of Chancellors, making a significant contribution to the ACR through a reorganisation of its Data Science Institute, enabling greater board communication and diversity of opinion. The ACR is "The Voice of Radiology" in matters of legislation and regulation, and is responsible for guiding radiology reimbursement and coding issues, including relative value units, managed care, alternative payment models, and Medicare regulations. Prior to this, Dr. McGinty headed up the ACR’s Commission on Economics. The Commission’s work often is used as background material and evidence for ACR congressional and state legislative efforts as well as communications with the CMS (Centers for Medicare & Medicaid Services), policy makers, and other medical insurers. Her corporate governance experience includes serving on the Board of NextGen Healthcare, and as a Non-Executive Director with the Industrial Development Authority (IDA) of the Republic of Ireland, chairing its Audit, Risk and Finance Committee. Dr. McGinty is also a member of the Governing Authority of the University of Galway in Ireland. In her various leadership roles, Dr. McGinty has been a powerful and influential voice for women in medical imaging. She has also been instrumental in identifying and mentoring radiologists who push to address health disparities in research, advocacy efforts, artificial intelligence development, and medical student recruitment. Dr. McGinty is highly qualified in clinical practice and management, possessing both a medical degree from the National University of Ireland and a master’s degree in business administration from Columbia University. Dr. McGinty’s academic stature is reflected in her appointment as Professor of Clinical Radiology at Weill Cornell Medicine where she is concurrently Senior Associate Dean of Clinical Affairs. In 2017, Dr. McGinty was appointed as founding Academic Director for the Executive MBA and Masters in Healthcare Leadership program delivered jointly by Weill Cornell and the Cornell University SC Johnson School of Business, a role she performed until 2019. Dr. McGinty’s published work has focused on payment models for imaging, most recently a bundled payment for breast cancer screening. Recently she has focused on the impact of Artificial Intelligence on Medical Imaging and has spoken at the Turing Institute and to the WHO Focus Group on AI in Healthcare on this topic. As a member of the American Medical Association’s Relative Value Unit Update Committee from 2012- 2016, Dr. McGinty was instrumental in recommending reimbursement policy to Medicare, thereby impacting the economics of the entire U.S. healthcare delivery system. In addition, from 2015 to 2021, Dr. McGinty was Chief Strategy and Contracting Officer within Weill Cornell responsible for fee-for-service and value-based payment arrangements.
공시 • Aug 294DMedical Limited, Annual General Meeting, Nov 02, 20234DMedical Limited, Annual General Meeting, Nov 02, 2023, at 10:00 AUS Eastern Standard Time.